(Published in Part II, Section 3, Sub Section (ii) of the
Gazette of India Extraordinary)
Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
(National Pharmaceuticals Pricing Authority)
New Delhi, the 9th May, 2016
ORDER
S.O.1688(E) – In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (6) of the table herein below as the retail price, exclusive of local taxes, if any in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company respectively, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Table
Sl. No. | Name of the Scheduled Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company respectively | Retail Price (Rs.) |
---|---|---|---|---|---|
(1) | (2) | (3) | (4) | (5) | (6) |
1 | Glimepiride+ Metformin HCl Tablet (Walaphage G1 Forte) |
Each uncoated bilayered tablet contains: Glimepiride-1mg Metformin HCl-1000mg ((as sustained release form) |
1 Tablet | M/s Macsot Health Series Pvt. Ltd. & M/s Wallace Pharmaceuticals Pvt. Ltd. |
5.93 |
2 | Glimepiride+ Metformin HCl Tablet (Walaphage G2 Forte) |
Each uncoated bilayered tablet contains: Glimepiride-2mg Metformin HCl-1000mg ((as sustained release form) |
1 Tablet | M/s Macsot Health Series Pvt. Ltd. & M/s Wallace Pharmaceuticals Pvt. Ltd. |
7.50 |
3 | Amoxycillin Trihydrate + Potassium Clavulanate Syrup (Ampilox CV 457) |
Each 5ml of the reconstituted suspension contains: Amoxycillin Trihydrate eq. to amoxicillin-400mg Potassium Clavulanate Diluted eq. to Clavulanic Acid-57mg |
1 ml | M/s Chiros Pharma & M/s Biochem Pharmaceuticals Industries Ltd. |
3.03 |
4 | Teneligliptin + Metformin HCl ER Tablet |
Each uncoated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin-20mg Metformin HCl-500mg (as extended release) |
Pack of 10 Tablets | M/s Glenmark Pharmaceuticals Ltd. & M/s Unichem Laboratories Ltd. |
111.43 |
5 | Teneligliptin + Metformin HCl ER Tablet (J- Ring M /Zilenta-M) |
Each uncoated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin-20mg Metformin HCl-500mg (as extended release) |
Pack of 10 Tablets | M/s Glenmark Pharmaceuticals Ltd. & M/s Indoco Remedies Ltd. |
111.43 |
6 | Teneligliptin + Metformin HCl ER Tablet (Tenepride M 500) |
Each uncoated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin-20mg Metformin HCl-500mg (as extended release) |
Pack of 10 Tablets | M/s Glenmark Pharmaceuticals Ltd. & M/s Micro Labs Ltd. |
111.43 |
7 | Teneligliptin + Metformin HCl ER Tablet (Eternex M 500) |
Each uncoated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin-20mg Metformin HCl-500mg (as extended release) |
Pack of 10 Tablets | M/s Glenmark Pharmaceuticals Ltd. & M/s Alembic Pharmaceuticals Ltd. |
111.43 |
8 | Teneligliptin + Metformin HCl ER Tablet (Afoglip M 500) |
Each uncoated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin-20mg Metformin HCl-500mg (as extended release) |
Pack of 10 Tablets | M/s Glenmark Pharmaceuticals Ltd. & M/s Torrent Pharmaceuticals Ltd. |
111.43 |
9 | Teneligliptin + Metformin HCl ER Tablet |
Each uncoated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin-20mg Metformin HCl-500mg (as extended release) |
Pack of 10 Tablets | M/s Glenmark Pharmaceuticals Ltd. & M/s Intas Pharmaceuticals Ltd. |
111.43 |
10 | Teneligliptin + Metformin HCl ER Tablet (Ten20 M 500) |
Each uncoated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin-20mg Metformin HCl-500mg (as extended release) |
Pack of 10 Tablets | M/s Glenmark Pharmaceuticals Ltd. & M/s Centaur Pharmaceuticals Pvt. Ltd. |
111.43 |
11 | Teneligliptin + Metformin HCl ER Tablet (Inogla M 500) |
Each uncoated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin-20mg Metformin HCl-500mg (as extended release) |
Pack of 10 Tablets | M/s Glenmark Pharmaceuticals Ltd. & M/s Wockhardt Ltd. |
111.43 |
NOTE :
- The manufacturers of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- The retail price for a pack of the aforesaid formulations shall be arrived at by the concerned manufacturers in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturers shall issue a price list in Form-V as per paragraph 24 (2) of the DPCO, 2013.
- The above mentioned retail price is applicable only to the individual manufacturers/marketeers as mentioned above i.e. who has applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.
- The concerned manufacturers of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of product in Form-III of Schedule-II of the DPCO, 2013. Manufacturers, in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- Consequent to the issue of retail price of the aforesaid formulations as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketeer prior to the above said date of notification, stand(s) superseded.
PN/162/30/2016/F
F.No. 8(30)/2016/D.P./NPPA-Div.II
(BALJIT SINGH)
Assistant Director
National Pharmaceutical Pricing Authority
Last Page Updated: 09-01-2019
Copyright © 2023 - All Rights Reserved- Official Website of National Pharmaceutical Pricing Authority Ministry of Chemicals and Fertilizers, Government of India
Note :Website Content Managed by National Pharmaceutical Pricing Authority Ministry of Chemicals and Fertilizers, Designed, Developed and Hosted by National Informatics Centre Services Inc.(NICSI)